Aimmune Therapeutics (NASDAQ:AIMT)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a research report issued to clients and investors on Friday. They currently have a $70.00 price objective on the biotechnology company’s stock. Wedbush’s price objective indicates a potential upside of 83.25% from the stock’s previous close.

Other analysts have also recently issued research reports about the stock. Roth Capital initiated coverage on shares of Aimmune Therapeutics in a research note on Monday, November 20th. They set a “buy” rating and a $60.00 price objective for the company. Zacks Investment Research raised shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $34.00 price objective for the company in a research note on Wednesday, November 8th. Piper Jaffray Companies set a $38.00 price objective on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research note on Saturday, October 21st. Credit Suisse Group upped their price objective on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the company an “outperform” rating in a research note on Monday, October 23rd. Finally, BidaskClub cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $49.40.

Aimmune Therapeutics (NASDAQ:AIMT) traded up $2.27 during mid-day trading on Friday, hitting $38.20. 569,200 shares of the stock were exchanged, compared to its average volume of 355,961. Aimmune Therapeutics has a twelve month low of $15.97 and a twelve month high of $38.86.

Aimmune Therapeutics (NASDAQ:AIMT) last released its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.09. research analysts forecast that Aimmune Therapeutics will post -2.57 EPS for the current fiscal year.

In other Aimmune Therapeutics news, insider Susan E. Barrowcliffe sold 18,390 shares of the business’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $22.00, for a total value of $404,580.00. Following the transaction, the insider now directly owns 3,223 shares in the company, valued at approximately $70,906. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Stephen George Dilly sold 1,154 shares of the business’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $26.24, for a total transaction of $30,280.96. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 317,720 shares of company stock valued at $8,400,244. 17.59% of the stock is owned by corporate insiders.

A number of large investors have recently bought and sold shares of AIMT. Jennison Associates acquired a new position in Aimmune Therapeutics in the 3rd quarter valued at about $5,077,000. Emerald Mutual Fund Advisers Trust boosted its holdings in Aimmune Therapeutics by 601.0% in the 4th quarter. Emerald Mutual Fund Advisers Trust now owns 282,355 shares of the biotechnology company’s stock valued at $5,209,000 after purchasing an additional 242,075 shares during the last quarter. Emerald Advisers Inc. PA boosted its holdings in Aimmune Therapeutics by 557.2% in the 4th quarter. Emerald Advisers Inc. PA now owns 270,358 shares of the biotechnology company’s stock valued at $4,988,000 after purchasing an additional 229,218 shares during the last quarter. California State Teachers Retirement System boosted its holdings in Aimmune Therapeutics by 1.4% in the 4th quarter. California State Teachers Retirement System now owns 20,593 shares of the biotechnology company’s stock valued at $380,000 after purchasing an additional 293 shares during the last quarter. Finally, American Century Companies Inc. boosted its holdings in Aimmune Therapeutics by 9.6% in the 4th quarter. American Century Companies Inc. now owns 90,205 shares of the biotechnology company’s stock valued at $1,664,000 after purchasing an additional 7,913 shares during the last quarter. Institutional investors own 73.38% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Aimmune Therapeutics (AIMT) Stock Rating Reaffirmed by Wedbush” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/12/01/aimmune-therapeutics-aimt-stock-rating-reaffirmed-by-wedbush.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.